Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novartis signs deal with Alteogen for drug delivery
The deal allows Novartis options for exclusive global rights to develop subcutaneous versions of products using ALT-B4. Credit: Michael Derrer Fuchs/Shutterstock.com.
The deal allows Novartis options for exclusive global rights to develop subcutaneous versions of products using ALT-B4. Credit: Michael Derrer Fuchs/Shutterstock.com.